Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

45.74 -0.20 (-0.44%)

Streaming Delayed Price Updated: 9:32 AM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9

...

82 83 Next >

Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...' ↗

August 01, 2025

President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences.

Via Benzinga

Topics Government

Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch ↗

July 31, 2025

Via Stocktwits

Topics Government

Bristol-Myers Squibb Unusual Options Activity For July 31 ↗

July 31, 2025

Via Benzinga

Why Bristol-Myers Squibb (BMY) Stock Is Trading Lower Today

July 31, 2025

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 4.2% in the afternoon session after the company lowered its full-year earnings forecast, overshadowing second-quarter results...

Via StockStory

Topics Intellectual Property World Trade

Meta, Microsoft Power Wall Street To New Records Despite Inflation Jump: What's Moving Markets Thursday? ↗

July 31, 2025

A post-earnings surge in Meta Platforms Inc. (NASDAQ:META) and Microsoft Corp.

Via Benzinga

Topics Economy

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q2, Full-Year Sales Guidance is Optimistic

July 31, 2025

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q2 CY2025, but sales were flat year on year at $12.27 billion. The company’s full-year revenue...

Via StockStory

Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion ↗

July 31, 2025

Bristol Myers beat Q2 sales expectations but cut its 2025 EPS forecast as strategic charges and legacy product declines weighed on earnings.

Via Benzinga

Bristol-Myers Squibb Co (NYSE:BMY) Surpasses Q2 2025 Earnings and Revenue Estimates, Shares Rise in Pre-Market Trading ↗

July 31, 2025

Bristol-Myers Squibb (BMY) beats Q2 2025 revenue and EPS estimates, driving a 2.9% pre-market stock surge. Strong oncology, immunology, and cardiovascular drug sales fuel growth.

Via Chartmill

BRISTOL-MYERS SQUIBB CO (NYSE:BMY) – A High-Yield Dividend Stock with Strong Profitability and Financial Health ↗

July 31, 2025

Bristol-Myers Squibb (BMY) offers a high 5.06% dividend yield, strong profitability, and solid financial health, making it a top pick for income investors. Its undervalued stock and consistent payout...

Via Chartmill

Bristol-Myers Squibb Earnings Preview ↗

July 30, 2025

Via Benzinga

Bristol Myers Squibb Reports Second Quarter Financial Results for 2025

July 31, 2025

From Bristol Myers Squibb

Via Business Wire

Stock Market Today: S&P 500, Nasdaq To Open Higher After Robust Meta, Microsoft Earnings—Investors Await Apple, Amazon Results ↗

July 31, 2025

U.S. stock futures rose on Thursday after ending on a mixed note on Wednesday. Futures of major benchmark indices were higher, except for the small-cap gauge Russell 2000.

Via Benzinga

Topics Stocks

Dow Falls Over 150 Points After Powell's Comments On Rate Cuts: Investor Sentiment Declines, But Fear Index Remains In 'Greed' Zone ↗

July 31, 2025

US stocks fell on Wednesday, with the Dow dropping over 150 points after Fed Chair Powell's comments. Fear Index remained in Greed zone.

Via Benzinga

Topics Economy Stocks

Microsoft, Apple And 3 Stocks To Watch Heading Into Thursday ↗

July 31, 2025

U.S. stock futures up, Apple, Amazon, Meta report strong earnings, Microsoft beats forecast, Bristol-Myers Squibb to release results.

Via Benzinga

Bristol Myers Squibb: A Stock with Potential Amid Challenges ↗

July 30, 2025

Via The Motley Fool

Got $500? 3 Blue Chip Dividend Stocks to Buy and Hold Forever ↗

July 30, 2025

Being a great investor doesn't have to be complicated or expensive.

Via The Motley Fool

Topics Intellectual Property

3 Low-Volatility Stocks We Find Risky

July 30, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

Bristol-Myers Squibb (BMY) Q2 Earnings: What To Expect

July 29, 2025

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results this Thursday morning. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients

July 28, 2025

From Bristol Myers Squibb

Via Business Wire

Why Is ATAI Life Sciences Stock Trading Lower On Monday? ↗

July 28, 2025

Recognify's CIAS trial for inidascamine missed its main endpoint but showed positive signals in cognitive domains and had a favorable safety profile.

Via Benzinga

Biotech Is Booming, and This Undervalued REIT Stands to Gain ↗

July 25, 2025

Via The Motley Fool

Explore the top gainers and losers within the S&P500 index in today's session. ↗

July 25, 2025

Let's delve into the developments on the US markets in the middle of the day on Friday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.

Via Chartmill

Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development

July 25, 2025

From Bristol Myers Squibb

Via Business Wire

Warren Buffett Owns 10 High-Yield Dividend Stocks. Here's the Best of the Bunch. ↗

July 25, 2025

Via The Motley Fool

2 Cash-Producing Stocks to Keep an Eye On and 1 We Find Risky

July 25, 2025

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

Topics Economy

Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)

July 24, 2025

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Supernus Pharmaceuticals (NASDAQ:SUPN) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Jim Cramer Praises Lowe's CEO, As For CrowdStrike: 'I'll See You At $1000' ↗

July 24, 2025

On CNBC's "Mad Money Lightning Round," Jim Cramer praised home improvement retailer Lowe's Companies and CrowdStrike Holdings.

Via Benzinga

Winners And Losers Of Q1: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks

July 23, 2025

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Zoetis (NYSE:ZTS) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Q1 Earnings Recap: Bristol-Myers Squibb (NYSE:BMY) Tops Branded Pharmaceuticals Stocks

July 23, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best...

Via StockStory

Topics Artificial Intelligence Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

82 83 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Bristol-Myers Squibb (NY:BMY)

All News about Bristol-Myers Squibb

Starting at $3.75/week.

Subscribe Today